Treating Onychomycosis with Efinaconazole: Considerations for Diverse Patient Groups
Journal of Fungi · 28.11.2025 · 11 (12) · 843
DOI: 10.3390/jof11120843 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Fungi, online erschienen am 28.11.2025. Verfasst von Aditya K Gupta und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Onychomycosis is a common nail disease that manifests with varying severity and frequency in specific patient populations, warranting a personalized treatment approach. Novel topical antifungals, such as efinaconazole 10% approved for use in North America and Japan, offer a safe treatment option for many of these patients, though real-world use requires special considerations. In this scoping review, a literature search was conducted in October 2025 using PubMed, Embase (Ovid), the Cochrane Central Register of Controlled Trials (CENTRAL), and Web of Science (Core Collection). In children and adolescents (≥6 years), efinaconazole 10% has shown higher efficacy rates than in adults, possibly attributed to less nail trauma, thinner nail plates, and faster nail growth. In the elderly, a mycological response can precede visual nail improvements, which may require extending treatment beyond the standard 48-week regimen, along with intermittent maintenance therapies. Although antifungal resistance is a concern, dermatophytes—including terbinafine-resistant strains—have generally shown high susceptibility to efinaconazole. In diabetic individuals, onychomycosis should be treated promptly to prevent secondary complications. Efinaconazole 10% showed similar efficacy in this population, regardless of glycemic control. In historically underserved populations, efinaconazole 10% showed no significant difference in efficacy for Latino/Hispanic patients, though further research is needed. Overall, efinaconazole 10% solution was well-tolerated across patient groups, with application-site reactions occurring without systemic sequalae. Healthcare providers are advised to check for concomitant tinea pedis, which increases the risk of relapse or re-infection, and advise patients on nail polish use, which may degrade after topical antifungal application. A shared decision-making framework can help improve treatment compliance and patient satisfaction.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Dermatology, Department of Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A1, Canada.
- Mediprobe Research Inc., London, ON N5X 2P1, Canada.
ORCID-Profile: Aditya K Gupta, Tong Wang, Elizabeth A Cooper
Zitieren
APA
Gupta, A. K., Taylor, D., Dennis, D., Wang, T., & Cooper, E. A. (2025). Treating Onychomycosis with Efinaconazole: Considerations for Diverse Patient Groups. Journal of Fungi, 11(12), 843. https://doi.org/10.3390/jof11120843
Vancouver
Gupta AK, Taylor D, Dennis D, Wang T, Cooper EA. Treating Onychomycosis with Efinaconazole: Considerations for Diverse Patient Groups. Journal of Fungi. 2025;11(12):843. doi:10.3390/jof11120843
BibTeX
@article{Gupta2025,
author = {Gupta, Aditya K and Taylor, Daniel and Dennis, Daniel and Wang, Tong and Cooper, Elizabeth A},
title = {Treating Onychomycosis with Efinaconazole: Considerations for Diverse Patient Groups},
journal = {Journal of Fungi},
year = {2025},
volume = {11},
number = {12},
pages = {843},
doi = {10.3390/jof11120843}
}
EUVIMED